ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The largest U.S. merchant manufacturer of phosgene, VanDeMark Chemical, has acquired Framochem, a Hungarian firm that is one of Europe’s leading makers of phosgene products. The purchase, for an undisclosed sum, reunites two companies that were previously owned by SNPE, the French state-owned chemical concern.
Although extremely hazardous to manufacture and transport, phosgene, COCI2, is a toxic yet critical raw material for many pharmaceutical, agricultural, and specialty chemical products. The deal will combine two of just a handful of merchant producers to create a company with 22,000 tons of annual capacity.
SNPE was a major phosgene manufacturer until a 2001 explosion near its French plant forced the firm to shut the site down. SNPE sold VanDeMark, based in Lockport, N.Y., to the private equity firm Buckingham Capital Partners in 2007. It then divested the rest of its fine chemicals business, including Framochem, to a German investment firm in 2010. Buckingham sold VanDeMark to another private equity firm, Uni-World, in 2012.
Bringing the two firms back together will expand VanDeMark geographically, while adding a phosgene chemicals catalog to its custom manufacturing business, says VanDeMark CEO Michael Kucharski. “All of which makes a compelling, single-source offering for our customers for phosgene products worldwide,” he adds.
Many chemical companies, especially producers of isocyanates, manufacture large quantities of phosgene for captive use. But very few offer the chemical on the merchant market, explains fine chemicals consultant Jan Ramakers.
VanDeMark was seeking growth through acquisition, Ramakers notes, and had little choice other than to buy its former sister company. The deal creates a dominant provider of an important chemical, he says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X